

1. Record Nr.	UNINA9910739430803321
Titolo	Molecular genetics of pancreatic cancer // Diane M. Simeone, Anirban Maitra, editors
Pubbl/distr/stampa	New York, : Springer, c2013
ISBN	1-4614-6549-4
Edizione	[1st ed. 2013.]
Descrizione fisica	1 online resource (235 p.)
Altri autori (Persone)	SimeoneDiane M MaitraAnirban
Disciplina	616.99437
Soggetti	Pancreas - Cancer - Molecular aspects Cancer - Genetic aspects
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	"Laboratory medicine."
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Genomic Alterations in Sporadic Pancreatic Cancer -- Molecular Pathology of Pancreatic Cancer Precursor Lesions -- Genetic Epidemiology and Pancreatic Cancer -- Translational Implications of Molecular genetics for Early Diagnosis of Pancreatic Cancer -- The Biology of K-Ras Signaling Pathways in Pancreatic Cancer -- Molecularly Targeted Therapies in Pancreatic Cancer -- Mouse Models of Pancreatic Cancer -- Genetics of Pancreatic Cancer Metastasis -- Epigenetic Alterations in Pancreatic Cancer -- New technologies in Molecular Characterization of Pancreatic Cancer -- Index.
Sommario/riassunto	Pancreatic cancer is a formidable disease, and advances in early detection and improved therapeutics have been slow to come forth. With new advances in molecular genetics in the field of pancreatic tumorigenesis, it is an opportune time to use these recent discoveries to enhance our understanding of pancreatic cancer biology and to improve outcomes in patients. In this volume, leading experts in the field shed light on these findings describing the mutational landscape of pancreatic cancer, including new inroads into our understanding of familial pancreatic cancer, epidemiology, the biology of K-ras signaling, and the emerging contribution of epigenetic alterations to disease initiation and progression. The distinctive pancreatic cancer-stroma ecosystem as determined by the dynamic interplay of inflammation,

hallmark mutations, EMT, and cancer stem cells is described, and implications of these interactions in the context of development of novel, personalized therapeutic options are explored.
